Zealand Pharma A/S (Zealand Pharma A/S) EV-to-Revenue : 110.76 (As of May. 02, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zealand Pharma A/S's enterprise value is $5,445.68 Mil. Zealand Pharma A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $49.17 Mil. Therefore, Zealand Pharma A/S's EV-to-Revenue for today is 110.76.

The historical rank and industry rank for Zealand Pharma A/S's EV-to-Revenue or its related term are showing as below:

ZLDPF' s EV-to-Revenue Range Over the Past 10 Years
Min: -5292.45 Med: 34.96 Max: 9643.61
Current: 110.76

During the past 13 years, the highest EV-to-Revenue of Zealand Pharma A/S was 9643.61. The lowest was -5292.45. And the median was 34.96.

ZLDPF's EV-to-Revenue is ranked worse than
85.06% of 1031 companies
in the Biotechnology industry
Industry Median: 7.91 vs ZLDPF: 110.76

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Zealand Pharma A/S's stock price is $87.66. Zealand Pharma A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.82. Therefore, Zealand Pharma A/S's PS Ratio for today is 106.38.

Zealand Pharma A/S EV-to-Revenue Historical Data

The historical data trend for Zealand Pharma A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S EV-to-Revenue Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

175.13

39.86

51.87

92.63

59.14

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															92.63	99.68	138.27	47.64	59.14

Competitive Comparison of Zealand Pharma A/S's EV-to-Revenue

For the Biotechnology subindustry, Zealand Pharma A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's EV-to-Revenue falls into.

Zealand Pharma A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Zealand Pharma A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	5445.681	/	49.165
	=	110.76

Zealand Pharma A/S's current Enterprise Value is $5,445.68 Mil.
Zealand Pharma A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $49.17 Mil.

Zealand Pharma A/S (OTCPK:ZLDPF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Zealand Pharma A/S's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	87.66	/	0.824
	=	106.38

Zealand Pharma A/S's share price for today is $87.66.
Zealand Pharma A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82.

Zealand Pharma A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.